Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone Propionate 10% Nasal Insert in Chronic Allergic Rhinitis
NCT07918404Phase 1Not yet recruiting
- Sponsor
- Dianosic
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Phase 1, single-arm trial of fluticasone propionate nasal spray in allergic rhinitis (AR), sponsored by Dianosic. Primary endpoint: Adverse Events at 194 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07918404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918404.